Department of Urology, the Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, China.
Asian J Androl. 2012 Jul;14(4):616-20. doi: 10.1038/aja.2012.22. Epub 2012 Apr 16.
Type 5 phosphodiesterase inhibitors (PDE5Is) are well known being effective via the nitric oxide and cyclic guanosine monophosphate (NO-cGMP) pathway and are widely used in the treatment of diabetic erectile dysfunction (ED). However, it is unclear whether other pathways may be involved in the treatment of diabetic ED with PDE5Is. The purpose of this study was to clarify the role of antioxidants in diabetic ED treatment through the long-term administration of PDE5Is. Three groups of Sprague-Dawley rats were utilized: Group N, the normal control; Group D, streptozotocin (STZ)-induced diabetic rats as a control; and Group D+T, STZ-induced diabetic rats who received oral administration of tadalafil for 8 weeks. Erectile function was assessed by intracavernous pressure (ICP) and mean arterial pressure (MAP) during electrical stimulation of the cavernous nerve before euthanasia. The levels of malondialdehyde (MDA), superoxide dismutase (SOD) and mitochondrial membrane potential (MMP) of cavernous tissue were assessed by biochemical analysis. The morphology of mitochondria was observed by electron microscopy. The ICP/MAP ratio was higher in Group D+T than in Group D (P<0.05). The levels of MDA decreased and the activities of SOD increased in Group D+T in comparison with Group D (P<0.05). The mitochondrial membrane potential level of cavernous tissue in diabetic rats was partially recovered by tadalafil treatment for 8 weeks. The morphology changes of mitochondria were also remarkably ameliorated in Group D+T. Collectively, the long-term administration of tadalafil in diabetic rats partially reduced oxidative stress lesions of the penis via a local antioxidative stress pathway. Long-term dosages of tadalafil given once daily beginning soon after the onset of diabetes may aid in preventing rats from developing diabetic ED.
5 型磷酸二酯酶抑制剂(PDE5Is)通过一氧化氮和环鸟苷单磷酸(NO-cGMP)途径被广泛用于治疗糖尿病性勃起功能障碍(ED),其有效性已得到广泛认可。然而,目前尚不清楚 PDE5Is 是否还通过其他途径来治疗糖尿病性 ED。本研究旨在通过长期应用 PDE5Is 来阐明抗氧化剂在治疗糖尿病性 ED 中的作用。研究使用了三组 Sprague-Dawley 大鼠:N 组,正常对照组;D 组,链脲佐菌素(STZ)诱导的糖尿病大鼠,作为对照组;D+T 组,给予 STZ 诱导的糖尿病大鼠口服他达拉非 8 周。在电刺激海绵体神经前处死大鼠,通过评估海绵体内压(ICP)和平均动脉压(MAP)来评估勃起功能。通过生化分析评估海绵体组织丙二醛(MDA)、超氧化物歧化酶(SOD)和线粒体膜电位(MMP)的水平。通过电子显微镜观察线粒体的形态。与 D 组相比,D+T 组的 ICP/MAP 比值更高(P<0.05)。与 D 组相比,D+T 组 MDA 水平降低,SOD 活性增加(P<0.05)。8 周的他达拉非治疗部分恢复了糖尿病大鼠海绵体组织的线粒体膜电位水平。D+T 组的线粒体形态变化也得到明显改善。总之,长期应用他达拉非可通过局部抗氧化应激途径部分减轻糖尿病大鼠阴茎的氧化应激损伤。糖尿病发病后早期开始每日 1 次给予他达拉非长期剂量治疗,可能有助于预防大鼠发生糖尿病性 ED。